Showing results (1-10 of 254) with videos related to
Sort By:
Pageof 26
Journal of Enzyme Inhibition and Medicinal Chemistry|November 22, 2002
N-substituted 4-(4-carboxyphenoxy)benzamides. Synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2Franck Picard, Rolf W HartmannArchiv Der Pharmazie|February 22, 2003
C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17alpha-hydroxylase-C17, 20-lyase: synthesis and biological evaluationSamer Haidar, Rolf W HartmannBioorganic & Medicinal Chemistry|December 14, 2001
5-Phenyl substituted 1-methyl-2-pyridones and 4'-substituted biphenyl-4-carboxylic acids. synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2Franck Picard, Tobias Schulz, Rolf W HartmannInternational Journal of Molecular Sciences|July 25, 2013
Recent progress in pharmaceutical therapies for castration-resistant prostate cancerLina Yin, Qingzhong Hu, Rolf W HartmannActa Crystallographica. Section E, Crystallographic Communications|February 13, 2016
Crystal structure of 4-methyl-sulfanyl-2-(2H-tetra-zol-2-yl)pyrimidineAndreas Thomann, Volker Huch, Rolf W HartmannExpert Opinion on Therapeutic Patents|June 4, 2015
Advances in the treatment of chronic wounds: a patent reviewChris J van Koppen, Rolf W HartmannJournal of Medicinal Chemistry|January 27, 2012
Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1Alessandro Spadaro, Martin Frotscher, Rolf W HartmannJournal of Computer-Aided Molecular Design|August 9, 2011
Computational investigation of the binding mode of bis(hydroxylphenyl)arenes in 17β-HSD1: molecular dynamics simulations, MM-PBSA free energy calculations, and molecular electrostatic potential mapsMatthias Negri, Maurizio Recanatini, Rolf W HartmannPlos One|August 14, 2010
Insights in 17beta-HSD1 enzyme kinetics and ligand binding by dynamic motion investigationMatthias Negri, Maurizio Recanatini, Rolf W HartmannJournal of Medicinal Chemistry|January 16, 2014
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseasesQingzhong Hu, Lina Yin, Rolf W HartmannPageof 26